Appeal No. 2005-1511
Application No. 09/879,398
Claims 6, 4 and 11 are representative of the subject matter on appeal and
read as follows:
6. A method of treating a patient with acute lymphoblastic leukemia
comprising the steps of:
obtaining a donor material comprising bone marrow or peripheral
blood collected from a donor;
depleting said donor material in vitro of αβ+ T cells, thereby rendering
the donor material rich in γδ+ T cells;
activating said γδ+ T cells in vitro by treating said cells with a media
comprising leukemia cells extracted from the patient and irradiated ex
vivo, alone or in combination with an anti-T cell receptor (TCR) pan-δ
antibody; and
administering an effective amount of said activated γδ+ T cells to said
leukemia patient, wherein said activated γδ+ T cells are cytolytic to the
patient’s leukemia cells but minimally cytotoxic to the patient’s other
cells.
4. The method in accordance with claim 6, wherein said activated γδ+ T
cells predominantly express the Vδ1 phenotype.
11. The method in accordance with claim 6, wherein said media consists
essentially of irradiated leukemia blast cells extracted from said
patient, an anti-TCR-pan-δ antibody, and interleukin-2.
The references relied upon by the examiner are:
Bell et al.(Bell) WO 98/33891 Aug. 6, 1998
Ensslin et al. (Ensslin), “Comparison of cytolytic and proliferative activities
of human γδ and αβ T cells from peripheral blood against various human
tumor cell lines,” J. of National Cancer Institute, Vol. 83, pp. 1564-1569
(1991).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007